This approval allows the company’s Chinese partner, China Bao Tai, to market Microcyn Technology as a technology that provides a moist environment for wounds and accelerates wound healing through the reduction of microorganisms in wounds. This approval follows the completion and submission of two randomized controlled Chinese clinical trials of Microcyn in December 2007.
Hoji Alimi, founder and CEO of Oculus, said: “The randomized trials in China followed by the Chinese State Food and Drug Administration (SFDA) approval provides Oculus with a significant business opportunity in terms of future sales while focusing our internal resources near term on the US clinical trials and new drug approval.
“The international business is a springboard that can provide Oculus with a stronger future financial model as our partners invest in clinical trials, sales, marketing and distribution of Microcyn Technology.”